Abstract Frontotemporal dementia is the second most common dementia among people under the age of 65.
Introduction
Our understanding of clinical and genetic aspects of frontotemporal dementia (FTD) has been significantly expanded over the last two decades. Approximately 35% to 50% of FTD patients have positive history of family members affected by FTD or other neurodegenerative disorders (Chow et al. 1999) . Several genes and a genetic locus have been identified. In our review, we discuss the phenotypic characteristics of these rare familial forms of FTD associated with parkinsonism (FTDP) including those with known genetic defects and those with unknown genes.
Familial FTDP with Known Genes
There are two pathogenic genes located on chromosome 17 associated with FTDP phenotype, microtubule-associated protein tau (MAPT), which causes frontotemporal dementia with parkinsonism linked to chromosome 17 with tau pathology (FTDP-17T/MAPT), and progranulin (PGRN), which causes frontotemporal dementia with parkinsonism linked to chromosome 17 with ubiquitin pathology (FTDP-17U/PGRN). The other pathogenic genes include chromatin modifying protein 2B (CHMP2B) causing FTD on chromosome 3 (FTD-3/CHMP2B), and fused in sarcoma (FUS) on chromosome 16 causing amyotrophic lateral sclerosis (ALS) with FTD (ALS-FTD/FUS). These last two genes only rarely produce FTDP phenotype. In addition, valosin-containing protein (VCP) gene causes FTD but without associated parkinsonism as far as it can be determined at the time of our writing. Therefore, it is not included in our review. It should be mentioned that all these diseases are rare and much more needs to be learned about clinical phenotypes and particularly clinical-genetic phenotypic correlations.
FTDP-17T/MAPT and FTDP-17U/PGRN
Since the original discovery of MAPT gene in 1998 (Hutton et al. 1998; Poorkaj et al. 1998; Spillantini et al. 1998) , 44 different pathogenic mutations have been identified. PGRN gene, which was discovered in 2006 Cruts et al. 2006 ), has at the present time 68 pathogenic mutations that have been identified (current listing of MAPT and PGRN mutations is available at http://www.molgen.ua. ac.be/FTDMutations) (AD&FTD Mutation Database 2011). Both genes are located on chromosome 17q21 approximately 1.7 Mb apart (PGRN is more centromeric to MAPT). The mode of inheritance for FTDP-17T/MAPT and FTDP-17U/ PGRN is autosomal dominant. The pathological characteristic of FTDP-17T/MAPT is tau-positive neuronal and glial inclusions. On the other hand, pathology of FTDP-17U/ PGRN is dominated by tau-negative but ubiquitin-positive neuronal inclusions that are also TDP-43 positive. The clinical features of FTDP-17T/MAPT and FTDP-17U/PGRN are summarized in Table 1 . The mean age of symptomatic disease onset for both, FTDP-17T/MAPT and FTDP-17U/ PGRN, is younger than for common forms of dementia such as Alzheimer's disease. However, FTDP-17T/MAPT symptomatic disease onset is about a decade earlier than for FTDP-17U/PGRN. The mean disease duration is similar, about 7 years. Both conditions usually present with behavioral and personality changes followed by dementia, but parkinsonism is more common in FTDP-17T/MAPT. Parkinsonism can even be a presenting clinical feature in FTDP-17T/MAPT. Parkinsonism is characterized by rigidity and bradykinesia with paucity of rest tremor (occasionally rest tremor can be seen particularly early in disease course). Levodopa therapy can be initially beneficial, but a sustained response is rarely present. Responsiveness to levodopa is more frequent in cases with FTDP-17T/MAPT.
FTD-3/CHMP2B
Gydesen and colleagues reported a large Danish family with autosomal dominant FTD-3 (Gydesen et al. 1987; Brown 1998; Ashworth et al. 1999; Gydesen et al. 2002) , and chromatin modifying protein 2B (CHMP2B) gene located on chromosome 3p11.2. FTD-3 is a rare form of FTD with only three CHMP2B confirmed pathogenic mutations (http:// www.molegen.ua.ac.be/FTDMutations). The mode of inheritance is autosomal dominant. The age of symptomatic disease onset is from 46 to 65 years with mean of 57 years (Brown et al. 2004 ). Disease duration is from 5 to 21 years with mean of 10 years (Holm et al. 2007 ). In the early stage of disease, patients typically present with behavioral/personality changes and occasionally with dyscalculia. In the late Usually not beneficial with few exception (and if so also early in disease course)
Unknown FTDP-17T/MAPT frontotemporal dementia with parkinsonism linked to chromosome 17 with tau pathology due to MAPT gene mutations, FTDP-17U/PGRN frontotemporal dementia with parkinsonism linked to chromosome 17 with ubiquitin pathology due to PGRN gene mutations, FTD-3/ CHMP2B frontotemporal dementia linked to chromosome 3 due to CHMP2B gene mutations, MAPT microtubule-associated protein tau, PGRN progranulin, CHMP2B chromatin modifying protein 2B, AAO age at onset, DD mean disease duration, AD autosomal dominant, B behavioral changes, C cognitive deficits, D dysphasia, E epilepsy, L language impairment, O oculomotor impairment, Pa Parkinsonism, Pe personality changes, Py pyramidal signs, Ps psychiatric symptoms, S semantic dementia, V visuospatial impairment, CBS corticobasal syndrome, MND motor neuron dysfunction (usually includes upper and lower motor neuron deficits) a This feature also could be an initial presentation stage of disease, particularly more than 4 years into the course of the illness, parkinsonian features such as rigidity, hypokinesia, reduced arm swing, and orofacial dyskinesia occur. The pyramidal signs can emerge in later stage of the illness in some patients (Gydesen et al. 2002; Ghanim et al. 2010) . The presence of orofacial dyskinesias and parkinsonism could be at least partially related to neuroleptic medications required to control behavioral disturbances in these patients. However, they tend to be persisting and even progress after discontinuation of neuroleptic medications indicating underlying dopaminergic deficits. Clinical features of FTD-3 are listed in Table 1 .
ALS-FTD/FUS
FUS gene mutations were initially identified in familial and sporadic ALS cases in 2009 (Kwiatkowski et al. 2009; Vance et al. 2009 ). The FUS gene is located on chromosome 16p11.2. So far, only a single patient with FTDP phenotype (no ALS) has been reported (van Langenhove et al. 2010 ). This 52-year-old female exhibited aberrant behavioral and personality changes followed by rigidity 3 years later. No information was provided in regard to presence of other parkinsonian signs or therapy with levodopa. She was a carrier of M254V missense mutation located on exon 6 of FUS gene. Additional FUS gene R521C missense mutation carrier was identified with complex phenotype consistent of ALS, dementia, and parkinsonism (Yan et al. 2010) . No details were provided about the specific features of parkinsonism in this case. Therefore, parkinsonism in carriers of FUS gene mutations is very rare and needs further delineation.
Familial FTDP with Known Linkage
At the present time, there is only one genetic locus located on chromosome 9 that is associated with FTDP phenotype.
FTDP with Linkage on Chromosome 9p
Vance et al. Table 1 .
Familial FTDP with Unknown Genetic Status
There are several disorders associated with the FTDP phenotype with unknown genes or linkage. In this review, we have chosen to discuss the familial progressive supranuclear palsy (PSP), hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS), and "overlap" syndrome. However, many other neurodegenerative disorders could be included in this category.
Familial PSP
Until very recently, PSP was considered to be a sporadic disorder (Davis et al. 1988 ). The community-based study from the Netherlands showed that up to 33% of cases are familial and out of those 7% demonstrate autosomaldominant inheritance (Donker Kaat et al. 2009 ). In this report, only a single case was found to be a carrier of MAPT P301L mutation. There are rare families with PSP/FTDP phenotype described in the literature dated back to before MAPT gene discovery in 1996 (examples include David et al. 1968; Mata et al. 1983; Ohara et al. 1992; Brown et al. 1993; de Yebenes et al. 1995; Tetrud et al. 1996; Gazeley and Maguire 1996) (David et al. 1968; Mata et al. 1983; Ohara et al. 1992; Brown et al. 1993; de Yebenes et al. 1995; Gazeley and Maguire 1996; Tetrud et al. 1996) . Based on the literature available for our review, it is unknown if the affected family members from those kindreds were examined for the genetic status after the identification of the MAPT and PGRN genes. There are also rare families with PSP/FTDP phenotype that were described after the identification of the MAPT gene that have been tested for MAPT carrier status with negative results (example include families described in Donker Kaat et al. (2009) Fig. 1 ). Therefore, it is reasonable to assume that more genes associated with PSP/FTDP phenotype and tau pathology will be found in the future. In the majority of these published and unpublished families, the mode of inheritance is autosomal dominant. The age of symptomatic disease onset is from 23 to 83 with mean of 64 years. The average disease duration is about 7.5 years. The ratio of male to female is 1 to 1.7. The clinical features of these cases usually resemble phenotype seen in sporadic PSP. However, behavioral impairments, personality abnormalities, and hallucinations are common in familial cases. Parkinsonism is usually symmetrical and is characterized by rigidity and bradykinesia with rest tremor seen infrequently. Levodopa therapy can be initially beneficial, but sustain response is rarely present. Additional clinical data are listed in Table 2 .
HDLS HDLS is a rare autosomal-dominant dysmyelination disease characterized by the presence of neuroaxonal swelling and spheroids (Wider et al. 2009 ). Eleven kindreds have been reported from seven countries including Sweden (Axelsson et al. 1984) , Japan (Yazawa et al. 1997; Terada et al. 2004; Itoh et al. 2006 ) the Netherlands (van der Knaap et al. 2000) , Australia (Hancock et al. 2003) , USA (Marotti et al. 2004; Baba et al. 2006; van Gerpen et al. 2008) , Germany (Mayer et al. 2007) , and Portugal (Mendes et al. 2010 ). However, genetic cause remains unknown. The age of symptomatic onset is from 15 to 78 years with mean of 39 years. The mean disease duration is approximately 9 years. Psychiatric symptoms, behavioral and personality changes, parkinsonism, epilepsy, pyramidal signs, and ataxia are common clinical features. Parkinsonism is usually asymmetrical and is characterized by rigidity and bradykinesia and sometimes accompanied with tremor and/or dystonia. The response to levodopa is poor. Additional clinical features are listed in Table 2 .
The term of "overlap" syndrome was coined by Uitti and colleagues in 1995 (Uitti et al. 1995) . Patients with this condition exhibit signs of parkinsonism, MND, and dementia (Uitti et al. 1995) . However, similar cases with complex phenotype were reported earlier as for example by Sercle and Kovarik, Yvonneau et al., Alter and Schaumann, Gilbert et al., and Eisen et al. (Sercle and Kovarik 1963; Yvonneau et al. 1971; Alter and Schaumann 1976; Gilbert et al. 1988; Eisen and Calne 1992) . More recently, additional cases were studied by Mochizuki et al., Kuzuhara and Kokubo, Imamura et al., Portera-Cailliau et al., Schweitzer et al., McCluskey et al., and Gilbert et al. (Mochizuki et al. 2004; Kuzuhara and Kokubo 2005; Imamura et al. 2007; Portera-Cailliau et al. 2007; McCluskey et al. 2009; Schweitzer et al. 2009; Gilbert et al. 2010) . Positive family history for other neurodegenerative conditions is common. The genetic cause for many of these families has also not yet been discovered. The mean age of symptomatic onset is about 60 years. The mean disease duration is about 10 years. Male and female ratio is 2 to 1. Parkinsonism is characterized by asymmetrical bradykinesia and rigidity and is frequently an initial presentation. The rest tremor is also seen. In the early stage of disease, dementia and pyramidal signs occur followed by motor neuron disease (MND). However, the sequence of development of particular features could be reversed with MND or dementia associated with personality and behavior changes seen first and then followed by parkinsonism. There are also cases with phenotype that includes only two out of three cardinal features of this syndrome (Hirano et al. 1966; Qureshi et al. 1996; Desai and Swash 1999; Zoccolella et al. 2002; Konagaya et al. 2003; Morimoto et al. 2009 ). Levodopa therapy can be beneficial for majority of these patients. Clinical features of "overlap" syndrome are listed in Table 2 .
Conclusion
Over the last two decades, tremendous progress has been achieved in better understanding of clinical and genetic aspect of familial forms of FTDP. Several genes, MAPT, PGRN, CHMP2B, and FUS, have been discovered allowing making a precise diagnosis in the clinical setting through genetic testing and counseling. However, there are still a number of families presenting with FTDP phenotype with unknown genetic cause. It remains to be seen if kindreds with FTD phenotype caused by the 43-kDa transactive response DNA binding protein (TARDBP) and VCP genes develop features of parkinsonism. In one family with TARDBP gene, vertical gaze palsy and choreiform movements of the upper extremities have been reported (Kovacs et al. 2009 ). Much needs to be learned about clinical-genetic correlations in these rare neurodegenerative disorders, albeit it is hoped that through studies of kindred curative treatments targeting specific genetic abnormalities in FTDP patients will be uncovered in the future.
